Endocrinology Drugs Market Report 2025

This Endocrinology Drugs market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The endocrinology drugs market size has grown strongly in recent years. It will grow from $33.26 billion in 2024 to $36.21 billion in 2025 at a compound annual growth rate (CAGR) of 8.86%. The growth during the historic period can be attributed to factors such as the rising global prevalence of diabetes, increased government initiatives, higher healthcare spending, a growing incidence of adrenal gland disorders, increased demand for insulin analogs, and a higher number of endocrinologists.

The endocrinology drugs market size is expected to see strong growth in the next few years. It will grow to $50.37 billion in 2029 at a compound annual growth rate (CAGR) of 8.60%. The expected growth during the forecast period can be attributed to factors such as a growing diabetic population, a higher prevalence of endocrine disorders, more adolescents facing hormonal imbalances, and increasing obesity rates. Key trends for the forecast period include advancements in technology, the adoption of advanced drug delivery systems, the integration of digital health solutions, precision medicine, and combination therapies.

The rising prevalence of endocrine diseases is driving the growth of the endocrinology drugs market. Endocrine diseases are disorders that affect the endocrine system, leading to imbalances in hormone production or regulation, which disrupt normal bodily functions. Factors contributing to the increasing prevalence of endocrine diseases include lifestyle changes, an aging population, and improvements in diagnostic methods, which have all led to greater recognition and incidence of these conditions. Endocrinology drugs are designed to manage these diseases by regulating hormone levels, addressing glandular dysfunction, and restoring hormonal balance, thus improving health outcomes. For example, in May 2023, the National Library of Medicine reported that approximately 13 million people in the U.S. (about 4.78% of the population) suffer from undiagnosed endocrine disorders, with thyroid disease being one of the most prevalent, affecting 30% to 40% of patients treated in endocrine practices. This growing prevalence of endocrine diseases is significantly driving the demand for endocrinology drugs.

Leading companies in the endocrinology drugs market are prioritizing the development of innovative products, such as ready-to-use vials, to enhance medication administration. These pre-filled and pre-dosed containers eliminate the need for reconstitution or preparation before use. For example, in December 2022, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, introduced Levothyroxine sodium injection in ready-to-use vials with a concentration of 100 mcg/mL. This formulation is designed for immediate application, reducing the risk of preparation errors and enhancing patient safety. It ensures precise and consistent dosing, which is essential for treating conditions such as hypothyroidism and myxedema coma. Additionally, these vials improve efficiency for healthcare providers by saving time and ensuring accurate administration in urgent care scenarios.

In July 2024, AstraZeneca, a UK-based pharmaceutical company, acquired Amolyt Pharma Inc., a France-based company specializing in therapies for rare endocrine diseases. This acquisition is aimed at strengthening AstraZeneca’s portfolio in rare endocrine diseases by integrating Amolyt Pharma's innovative pipeline of late-stage therapies. This move highlights the ongoing efforts by major pharmaceutical companies to expand their capabilities and offerings in the growing market for endocrinology drugs.

Major players in the endocrinology drugs market are Johnson & Johnson Inc., Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Novartis International AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Biocon Limited, Boehringer Ingelheim International GmbH, Mylan N.V., Sandoz International GmbH, Ipsen Pharma, Ferring Pharmaceuticals Inc., Endocrine Pharma Private Limited.

North America was the largest region in the endocrinology drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in endocrinology drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the endocrinology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Endocrinology drugs are pharmaceutical treatments designed to manage and regulate disorders associated with the endocrine system, which includes glands such as the thyroid, pancreas, and adrenal glands. These drugs are used to treat conditions such as diabetes, thyroid disorders, growth hormone deficiencies, and hormonal imbalances, aiming to restore normal hormonal levels and improve the overall function of the endocrine system.

The primary conditions treated with endocrinology drugs include hyperthyroidism, hypothyroidism, diabetes, polycystic ovarian syndrome, growth hormone disorders, and pituitary gland disorders, among others. Hyperthyroidism, for example, is marked by an overproduction of thyroid hormones, causing symptoms such as weight loss, rapid heartbeat, and anxiety. Key therapy areas include diabetes medications, thyroid hormone disorder treatments, human growth hormone, testosterone replacement therapy, and others. These drugs are distributed through various channels, such as hospital pharmacies, online pharmacies, and retail pharmacies, and are used by a range of end users, including hospitals, ambulatory surgical centers, and more.

The endocrinology drugs market research report is one of a series of new reports that provides endocrinology drugs market statistics, including endocrinology drugs industry global market size, regional shares, competitors with an endocrinology drugs market share, detailed endocrinology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the endocrinology drugs industry. This endocrinology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The endocrinology drugs market consists of sales of insulin analogs, antithyroid drugs, and anti-diabetic drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.